Recent studies have further established that CD38 monoclonal antibodies, such as daratumumab and isatuximab, can induce apoptosis of myeloma cells, promote clonal T-cell expansion, and modulate the tumor immune microenvironment, thus supporting their role as effective immunotherapeutic agents (38, 43). Here, CD38 is linked to plasma cell myeloma.